MX2020005128A - Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos. - Google Patents

Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.

Info

Publication number
MX2020005128A
MX2020005128A MX2020005128A MX2020005128A MX2020005128A MX 2020005128 A MX2020005128 A MX 2020005128A MX 2020005128 A MX2020005128 A MX 2020005128A MX 2020005128 A MX2020005128 A MX 2020005128A MX 2020005128 A MX2020005128 A MX 2020005128A
Authority
MX
Mexico
Prior art keywords
immunoglobulin
ilt3
antibodies specific
transcript
lilrb4
Prior art date
Application number
MX2020005128A
Other languages
English (en)
Inventor
Laurence Fayadat-Dilman
Veronica Juan
Carl Mieczkowski
Michael A Meehl
Philip E Brandish
Latika Singh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020005128A publication Critical patent/MX2020005128A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales no promiscuos humanizados específicos para el transcrito similar a la inmunoglobulina tipo 3 (ILT3), también conocido como receptor de tipo inmunoglobulina de leucocitos de la subfamilia B miembro 4 (LILRB4).
MX2020005128A 2017-11-17 2018-11-15 Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos. MX2020005128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587604P 2017-11-17 2017-11-17
PCT/US2018/061165 WO2019099597A2 (en) 2017-11-17 2018-11-15 Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof

Publications (1)

Publication Number Publication Date
MX2020005128A true MX2020005128A (es) 2020-07-27

Family

ID=64572590

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005128A MX2020005128A (es) 2017-11-17 2018-11-15 Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
MX2025000940A MX2025000940A (es) 2017-11-17 2020-07-13 Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025000940A MX2025000940A (es) 2017-11-17 2020-07-13 Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos

Country Status (26)

Country Link
US (6) US11111297B2 (es)
EP (1) EP3710479A2 (es)
JP (1) JP7194481B2 (es)
KR (1) KR102478433B1 (es)
CN (2) CN111712518B (es)
AR (1) AR113696A1 (es)
AU (1) AU2018367524B2 (es)
BR (1) BR112020009759A8 (es)
CA (1) CA3082409A1 (es)
CL (1) CL2020001240A1 (es)
CO (1) CO2020006405A2 (es)
CR (1) CR20200204A (es)
DO (1) DOP2020000074A (es)
EA (1) EA202091228A1 (es)
EC (1) ECSP20032082A (es)
GE (2) GEP20237565B (es)
IL (1) IL274574A (es)
JO (1) JOP20200131A1 (es)
MA (1) MA50900A (es)
MX (2) MX2020005128A (es)
NI (1) NI202000036A (es)
PE (1) PE20210475A1 (es)
PH (1) PH12020550890A1 (es)
SG (1) SG11202004426SA (es)
TW (1) TWI816715B (es)
WO (1) WO2019099597A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
JP7194481B2 (ja) * 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
US11760802B2 (en) * 2019-12-19 2023-09-19 Ngm Biopharmaceuticals, Inc. ILT3-binding agents and methods of use thereof
AU2021265801B2 (en) 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof
AU2022239502A1 (en) * 2021-03-19 2023-10-05 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US20250101097A1 (en) * 2021-07-28 2025-03-27 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CN116082502A (zh) * 2021-11-08 2023-05-09 复旦大学 Galectin8与LILRB4结合的调节剂及其应用
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
CN119213023A (zh) 2022-03-29 2024-12-27 恩格姆生物制药公司 Ilt3和cd3结合剂以及其使用方法
EP4514472A1 (en) 2022-04-25 2025-03-05 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
CN115925941B (zh) * 2022-06-08 2026-04-03 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
EP4714975A1 (en) 2023-05-18 2026-03-25 Nanjing Leads Biolabs Co., Ltd. Antibody binding lilrb4 and cd3, and use thereof
WO2025062392A1 (en) 2023-09-20 2025-03-27 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025141589A1 (en) 2023-12-31 2025-07-03 Biond Biologics Ltd. Treatment of cancer with anti-ilt3 antibodies

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3162749D1 (en) 1980-06-30 1984-04-26 Ibm Data transfer apparatus
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
AU2002345878A1 (en) * 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2391438A1 (en) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
EP1799840A4 (en) * 2004-09-03 2009-02-18 Univ Columbia ILT3-POLYPEPTIDES AND USES THEREOF
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
ES2547463T3 (es) * 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20130494T1 (en) * 2005-12-20 2013-08-31 Sbi Biotech Co., Ltd. Anti-ilt7 antibody
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
GB0705775D0 (en) 2007-03-26 2007-05-02 Affitech As Product
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
CN101830978A (zh) * 2009-03-09 2010-09-15 中国科学院微生物研究所 一种人免疫球蛋白样受体突变体及其应用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
AU2011241483B2 (en) 2010-04-16 2015-06-25 Carina Biotech Pty Ltd Proteins that bind PI16 and uses thereof
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
US9696312B2 (en) * 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2014189973A2 (en) 2013-05-20 2014-11-27 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016127427A1 (zh) 2015-02-15 2016-08-18 华为技术有限公司 电子设备外壳的加工方法、电子设备外壳及电子设备
AU2016229201B2 (en) 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
EP3325006A4 (en) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
EP3507601B1 (en) 2016-08-31 2023-08-16 Agency for Science, Technology and Research Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc"
WO2018089300A1 (en) * 2016-11-10 2018-05-17 Merck Sharp & Dohme Corp. Ilt3 ligand
EP3580239A4 (en) 2017-02-09 2021-07-28 Bluefin Biomedicine, Inc. ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
JP7194481B2 (ja) * 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
AU2022239502A1 (en) * 2021-03-19 2023-10-05 Merck Sharp & Dohme Llc Methods for treating cancer with anti-ilt3 antibodies
US20250101097A1 (en) * 2021-07-28 2025-03-27 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CA3227993A1 (en) * 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor
WO2023235699A1 (en) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
EP4561623A1 (en) * 2022-07-28 2025-06-04 Merck Sharp & Dohme LLC Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies

Also Published As

Publication number Publication date
KR102478433B1 (ko) 2022-12-15
SG11202004426SA (en) 2020-06-29
NI202000036A (es) 2020-09-24
CR20200204A (es) 2020-06-18
JP7194481B2 (ja) 2022-12-22
DOP2020000074A (es) 2020-08-31
US20220010010A1 (en) 2022-01-13
MX2025000940A (es) 2025-03-07
BR112020009759A8 (pt) 2023-01-31
CN111712518A (zh) 2020-09-25
CO2020006405A2 (es) 2020-06-09
TW201922786A (zh) 2019-06-16
US20220025042A1 (en) 2022-01-27
EP3710479A2 (en) 2020-09-23
PH12020550890A1 (en) 2021-04-12
AU2018367524A1 (en) 2020-06-11
AR113696A1 (es) 2020-06-03
US20220025043A1 (en) 2022-01-27
JOP20200131A1 (ar) 2020-05-28
US20220010011A1 (en) 2022-01-13
US20190153093A1 (en) 2019-05-23
BR112020009759A2 (pt) 2020-11-03
AU2018367524B2 (en) 2022-09-15
WO2019099597A3 (en) 2019-06-13
EA202091228A1 (ru) 2020-08-12
CA3082409A1 (en) 2019-05-23
MA50900A (fr) 2020-09-23
US12441792B2 (en) 2025-10-14
CN120058946A (zh) 2025-05-30
JP2021503280A (ja) 2021-02-12
GEP20237565B (en) 2023-11-10
TWI816715B (zh) 2023-10-01
US12435133B2 (en) 2025-10-07
PE20210475A1 (es) 2021-03-08
US20220033497A1 (en) 2022-02-03
CN111712518B (zh) 2025-03-25
CL2020001240A1 (es) 2020-12-18
GEAP202315366A (en) 2023-07-25
KR20200083598A (ko) 2020-07-08
US11111297B2 (en) 2021-09-07
WO2019099597A2 (en) 2019-05-23
ECSP20032082A (es) 2020-08-31
IL274574A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2020005128A (es) Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
ZA202211577B (en) Multivalent and multispecific 41bb-binding fusion proteins
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
MX2021012720A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
CO2017006740A2 (es) Anticuerpos anti–cd79b
MX2018001398A (es) Anticuerpos monoclonales contra bcma.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
MX2023002379A (es) Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
IL284091A (en) Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
MX2019011225A (es) Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
NZ758360A (en) Btla agonist antibodies and uses thereof
MX382543B (es) Nuevos anticuerpos dirigidos al receptor iib de fc gamma y al receptor de fc epsilon
NZ763061A (en) Anti-ox40 antibodies and uses thereof
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
MX384990B (es) Selectividad eficaz de proteínas recombinantes.
BR112017010521A2 (pt) composições catalisadoras à base de cromo para polimerização de olefina
EA201992003A1 (ru) Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину